Drug Profile
Polyclonal antibody hyperGAMCF
Latest Information Update: 10 Jul 1996
Price :
$50
*
At a glance
- Originator Nabi Biopharmaceuticals
- Class Antibacterials; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Most Recent Events
- 10 Jul 1996 North American Biologicals is now called NABI
- 10 Jul 1996 Discontinued-II for Cystic fibrosis-associated respiratory tract infections in USA (IV)
- 10 Jul 1996 Discontinued-II for Pseudomonal infections in USA (IV)